Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Weisel, Katja"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 48
Tytuł:
Guidelines for the Use and Reporting of Patient-Reported Outcomes in Multiple Myeloma Clinical Trials.
Autorzy:
Laane E; Hematology-Oncology Clinic, Tartu University, 50406 Tartu, Estonia.
Salek S; School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK.
Oliva EN; U.O.C. Ematologia, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, 89124 Reggio di Calabria, Italy.
Bennink C; Department of Hematology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
Clavreul S; Myeloma Patients Europe, 1050 Brussels, Belgium.
Richardson PG; Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA 02215, USA.
Scheid C; Department of Internal Medicine I, University of Cologne, 50923 Cologne, Germany.
Weisel K; Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Ionova T; Quality of Life Unit, Saint Petersburg State University Hospital, 190103 Saint Petersburg, Russia.
Pokaż więcej
Corporate Authors:
European Hematology Association Specialized Working Group on Quality of Life and Symptoms
Źródło:
Cancers [Cancers (Basel)] 2023 Dec 08; Vol. 15 (24). Date of Electronic Publication: 2023 Dec 08.
Typ publikacji:
Guideline
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial.
Autorzy:
Leypoldt LB; Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Gavriatopoulou M; Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Besemer B; Department of Hematology, Oncology, Immunology, Rheumatology, University Hospital of Tuebingen, 72076 Tuebingen, Germany.
Salwender H; Asklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, 22763 Hamburg, Germany.
Raab MS; Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Nogai A; Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie, Charité-Universitätsmedizin Berlin, 12200 Berlin, Germany.
Khandanpour C; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany.; Department of Hematology and Oncology, University Hospital Schleswig-Holstein and University of Lübeck, 23538 Lübeck, Germany.
Runde V; Department of Hematology, Oncology and Palliative Care, Wilhelm-Anton-Hospital, 47574 Goch, Germany.
Jauch A; Institute of Human Genetics, University of Heidelberg, 69120 Heidelberg, Germany.
Zago M; Center for Clinical Trials, University Hospital of Tuebingen, 72070 Tuebingen, Germany.
Martus P; Department of Clinical Epidemiology and Applied Biostatistics, Eberhard Karls University of Tuebingen, 72076 Tuebingen, Germany.
Goldschmidt H; Internal Medicine V and GMMG-Study Group, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Bokemeyer C; Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Weisel KC; Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2023 Sep 21; Vol. 15 (18). Date of Electronic Publication: 2023 Sep 21.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients.
Autorzy:
Avivi I; Department of Hematology, Tel Aviv Sourasky Medical Center and Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Vesole DH; Hackensack University Medical Center, New Jersey Medical School, Rutgers University, Hackensack, NJ 07601, USA.
Davila-Valls J; Hospital Nuestra Señora de Sonsoles, 05004 Ávila, Spain.
Usnarska-Zubkiewicz L; Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Olszewska-Szopa M; Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Milunovic V; Division of Hematology, Clinical Hospital Merkur, 10000 Zagreb, Croatia.
Baumert B; Department of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland.
Osękowska B; Department of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland.
Kopińska A; Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, 40-032 Katowice, Poland.
Gentile M; Hematology Unit AO of Cosenza, Cosenza and Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.
Puertas-Martinez B; Instituto de Investigación Biomédica de Salamanca (IBSAL), Cancer Research Center-IBMCC (USAL-CSIC), CIBERONC, University Hospital of Salamanca, 37007 Salamanca, Spain.
Robak P; Department of Hematology, Copernicus Memorial Hospital, Medical University of Lodz, 90-752 Lodz, Poland.
Crusoe E; Universidade Federal da Bahia, Hospital Universitário Professor Edgar Santos, Serviço de Hematologia, Salvador 40110-909, BA, Brazil.
Rodriguez-Lobato LG; Amyloidosis and Multiple Myeloma Unit, Department of Hematology, Hospital Clínic of Barcelona, IDIBAPS, 08036 Barcelona, Spain.
Gajewska M; Department of Internal Medicine and Hematology, Military Institute of Medicine, 04-141 Warsaw, Poland.
Varga G; Department of Internal Medicine and Haematology, Semmelweis University, 1085 Budapest, Hungary.
Delforge M; University Hospitals (UZ) Leuven, 3000 Leuven, Belgium.
Cohen Y; Department of Hematology, Tel Aviv Sourasky Medical Center and Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Gozzetti A; Department of Medical Science, Surgery and Neuroscience, University of Siena, 53100 Siena, Italy.
Pena C; Sección Hematología, Hospital del Salvador, Santiago 13123, Chile.
Shustik C; Royal Victoria Hospital, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
Mikala G; Department of Hematology and Stem Cell Transplantation, National Institute for Hematology and Infectious Diseases, South Pest Central Hospital, 1097 Budapest, Hungary.
Zalac K; Department of Hematology, Clinics for Internal Medicine, University Hospital Center 'Sestre Milosrdnice', 10000 Zagreb, Croatia.
Alexander HD; Personalised Medicine Centre, School of Medicine, Ulster University, Derry/Londonderry BT47 6SB, UK.
Barth P; Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA.
Weisel K; Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Medical-Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Martínez-López J; Nieves Lopez-Muñoz Hospital, 28029 Madrid, Spain.
Waszczuk-Gajda A; Department of Hematology, Oncology and Internal Diseases, Warsaw Medical University, 02-097 Warsaw, Poland.
Krzystański M; Independent IT Specialist, 31-864 Krakow, Poland.
Jurczyszyn A; Department of Hematology, Jagiellonian University Medical College, 31-155 Crakow, Poland.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2023 Sep 01; Vol. 15 (17). Date of Electronic Publication: 2023 Sep 01.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Real-world study on adoption of standard-of-care for transplant-eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy.
Autorzy:
Weisel K; Department of Oncology, Hematology, BMT with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Wadlund AO; Janssen-Cilag AB, Solna, Sweden.
Gungor G; Janssen, Kavacık, Beykoz/İstanbul, Turkey.
Dergarabetian E; Janssen-Cilag Limited, Buckinghamshire, UK.
Pacheco C; Cerner Enviza France SAS, Paris, France.
Masurkar N; Cerner Enviza France SAS, Paris, France.
Rodriguez-Otero P; Department of Hematology, Clínica Universidad de Navarra, Pamplona, Navarra, Spain.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2022 Oct; Vol. 109 (4), pp. 388-397. Date of Electronic Publication: 2022 Jul 12.
Typ publikacji:
Journal Article; Observational Study
MeSH Terms:
Multiple Myeloma*/diagnosis
Multiple Myeloma*/epidemiology
Multiple Myeloma*/therapy
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bortezomib/therapeutic use ; Dexamethasone/therapeutic use ; Humans ; Spain/epidemiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Carfilzomib 56 mg/m twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison.
Autorzy:
Weisel K; Department of Oncology and Hematology, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany.
Nooka AK; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Terpos E; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Spencer A; Australian Centre for Blood Diseases, Monash University, Malignant Haematology & Stem Cell Transplantation, Alfred Hospital and Department of Clinical Haematology, Monash University, Melbourne, Australia.
Goldschmidt H; Internal Medicine V and National Center of Tumor Diseases, University Clinic Heidelberg, Heidelberg, Germany.
Dirnberger F; Global Value and Access, Amgen GmbH, Munich, Germany.
DeCosta L; Global Biostatistical Science, Amgen Ltd., Uxbridge, UK.
Yusuf A; Global Medical Affairs, Amgen Inc., Thousand Oaks, CA, USA.
Kumar S; Department of Internal Medicine, Division of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Aug; Vol. 63 (8), pp. 1887-1896. Date of Electronic Publication: 2022 Mar 15.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Multiple Myeloma*/drug therapy
Antibodies, Monoclonal ; Bortezomib/therapeutic use ; Dexamethasone/therapeutic use ; Humans ; Lenalidomide/therapeutic use ; Neoplasm Recurrence, Local/drug therapy ; Oligopeptides
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress.
Autorzy:
Modemann F; Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.; Mildred Scheel Cancer Career Center, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
Ghandili S; Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
Schmiedel S; The I. Department of Internal Medicine, Division of Infectious Diseases, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
Weisel K; Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
Bokemeyer C; Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
Fiedler W; Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2022 Jul 29; Vol. 14 (15). Date of Electronic Publication: 2022 Jul 29.
Typ publikacji:
Journal Article; Review
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies.
Autorzy:
Modemann F; Department of Oncology, Hematology and Bone Marrow Transplantation with Division of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Mildred Scheel Cancer Career Center, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Niederwieser C; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Weisel K; Department of Oncology, Hematology and Bone Marrow Transplantation with Division of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Bokemeyer C; Department of Oncology, Hematology and Bone Marrow Transplantation with Division of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Fiedler W; Department of Oncology, Hematology and Bone Marrow Transplantation with Division of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ghandili S; Department of Oncology, Hematology and Bone Marrow Transplantation with Division of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Mar; Vol. 63 (3), pp. 664-671. Date of Electronic Publication: 2021 Oct 20.
Typ publikacji:
Journal Article
MeSH Terms:
COVID-19*/complications
Hematologic Neoplasms*/complications
Hematologic Neoplasms*/epidemiology
Hematologic Neoplasms*/therapy
Influenza, Human*/complications
Influenza, Human*/diagnosis
Influenza, Human*/epidemiology
Humans ; SARS-CoV-2 ; Seasons
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Autorzy:
Richardson PG; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Schjesvold F; Oslo Myeloma Center at Oslo University Hospital, KG Jebsen Center for B-Cell Malignancies, University of Oslo, Oslo, Norway.
Weisel K; Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Moreau P; University Hospital Hôtel-Dieu, Nantes, France.
Anderson LD Jr; University of Texas Southwestern Medical Center, Dallas, Texas, USA.
White D; Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.
Rodriguez-Otero P; Clinica Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain.
Sonneveld P; Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Engelhardt M; Universitätsklinikum Freiburg, Freiburg, Germany.
Jenner M; Southampton General Hospital, Southampton, UK.
Corso A; Policlinico San Matteo Universita Di Pavia, Pavia, Italy.
Dürig J; University Hospital Essen, Essen, Germany.
Pavic M; Centre Hospitalier Universitaire De Sherbrooke (CHUS), Centre de Recherche Clinique Etienne-Le Bel (CRCELB) Hopital Fleurimont, Sherbrooke, QC, Canada.
Salomo M; Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Beksac M; Ankara University, Ankara, Turkey.
Oriol A; Institut Català d'Oncologia I Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain.
Lindsay J; East Kent Hospitals University NHS Foundation Trust, Kent and Canterbury Hospital, Canterbury, UK.
Liberati AM; University of Perugia, Perugia, Italy.
Galli M; Ospedale Papa Giovanni XXIII, U.O. di Ematologia, Ispedali Riuniti di Bergamo, Bergamo, Italy.
Robak P; Medical University of Lodz, Lodz, Poland.
Larocca A; A.O.U. Citta della Salute e della Scienza di Torino, Torino, Italy.
Yagci M; Gazi University Medical Faculty, Ankara, Turkey.
Vural F; Ege University, Izmir, Turkey.
Kanate AS; West Virginia University, Morgantown, West Virginia, USA.
Jiang R; Bristol Myers Squibb, Princeton, New Jersey, USA.
Grote L; Bristol Myers Squibb, Princeton, New Jersey, USA.
Peluso T; Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland.
Dimopoulos M; National and Kapodistrian University of Athens, Athens, Greece.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2022 Jan; Vol. 108 (1), pp. 73-83. Date of Electronic Publication: 2021 Sep 22.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Multiple Myeloma/*drug therapy
Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib/administration & dosage ; Dexamethasone/administration & dosage ; Drug Resistance, Neoplasm ; Female ; Humans ; Lenalidomide/therapeutic use ; Male ; Middle Aged ; Multiple Myeloma/mortality ; Multiple Myeloma/pathology ; Prognosis ; Recurrence ; Retreatment ; Thalidomide/administration & dosage ; Thalidomide/analogs & derivatives ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma.
Autorzy:
Siegel D; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
Weisel K; Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Zahlten-Kumeli A; Amgen Inc, Thousand Oaks, CA, USA.
Medhekar R; Amgen Inc, Thousand Oaks, CA, USA.
Ding B; Amgen Inc, Thousand Oaks, CA, USA.
Leleu X; CHU de Poitiers - La Miletrie, Poitiers, France.; INSERM CIC 1402, Poitiers, France.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2021 Dec; Vol. 62 (12), pp. 3002-3010. Date of Electronic Publication: 2021 Jun 26.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Multiple Myeloma*/diagnosis
Multiple Myeloma*/drug therapy
Multiple Myeloma*/etiology
Quality of Life*
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Dexamethasone/therapeutic use ; Humans ; Likelihood Functions
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma.
Autorzy:
Ghandili S; The Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg, 20251 Hamburg, Germany.
Schönlein M; The Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg, 20251 Hamburg, Germany.
Wiessner C; The Institute for Medical Biometry and Epidemiology, 20251 Hamburg, Germany.
Becher H; The Institute for Medical Biometry and Epidemiology, 20251 Hamburg, Germany.
Lütgehetmann M; The Institute of Medical Microbiology, Virology and Hygiene, 20251 Hamburg, Germany.; The German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, 20251 Hamburg, Germany.
Brehm TT; The German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, 20251 Hamburg, Germany.; The I. Department of Internal Medicine, Division of Infectious Diseases, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
Schulze Zur Wiesch J; The German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, 20251 Hamburg, Germany.; The I. Department of Internal Medicine, Division of Infectious Diseases, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
Bokemeyer C; The Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg, 20251 Hamburg, Germany.
Sinn M; The Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg, 20251 Hamburg, Germany.
Weisel KC; The Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg, 20251 Hamburg, Germany.
Leypoldt LB; The Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg, 20251 Hamburg, Germany.
Pokaż więcej
Źródło:
Journal of clinical medicine [J Clin Med] 2021 Nov 24; Vol. 10 (23). Date of Electronic Publication: 2021 Nov 24.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma.
Autorzy:
Rodriguez-Otero P; Clínica Universidad de Navarra, Pamplona, Spain.
Ayers D; PRECISIONheor, Vancouver, BC, Canada.
Cope S; PRECISIONheor, Vancouver, BC, Canada.
Davies FE; NYU Langone Health, New York, NY, USA.
Delforge M; Department of Hematology, University Hospital Leuven, Leuven, Belgium.
Mojebi A; PRECISIONheor, Vancouver, BC, Canada.
Jansen JP; PRECISIONheor, Vancouver, BC, Canada.
Weisel K; Department of Oncology, Hematology & Bone Marrow Transplantation, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany.
Hege K; Bristol Myers Squibb, Princeton, NJ, USA.
Dhanasiri S; Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2021 Oct; Vol. 62 (10), pp. 2482-2491. Date of Electronic Publication: 2021 Apr 24.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Multiple Myeloma*/drug therapy
Antibodies, Monoclonal, Humanized ; Dexamethasone ; Humans ; Hydrazines ; Triazoles ; United States
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial.
Autorzy:
Klein EM; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.; Department of Internal Medicine 5, Klinikum Nuremberg, Paracelsus Medical University, 90419 Nuremberg, Germany.
Tichy D; Division of Biostatistics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Salwender HJ; Asklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, 22763 Hamburg, Germany.
Mai EK; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.
Duerig J; Department of Hematology, University Clinic Essen, 45147 Essen, Germany.
Weisel KC; Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Benner A; Division of Biostatistics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Bertsch U; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.; National Center for Tumor Diseases, 69120 Heidelberg, Germany.
Akhavanpoor M; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.
Besemer B; Department of Hematology, Oncology and Immunology, University Hospital Tübingen, 72076 Tübingen, Germany.
Munder M; Department of Internal Medicine III, University Medical Center Mainz, 55131 Mainz, Germany.
Lindemann HW; Department of Hematology and Oncology, Katholisches Krankenhaus Hagen, 58097 Hagen, Germany.
Hose D; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.
Seckinger A; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.
Luntz S; Coordination Centre for Clinical Trials (KKS) Heidelberg, 69120 Heidelberg, Germany.
Jauch A; Institute of Human Genetics, University of Heidelberg, 69120 Heidelberg, Germany.
Elmaagacli A; Department of Hematology and Oncology, Asklepios Hospital Hamburg St. Georg, 20099 Hamburg, Germany.
Fuhrmann S; Department of Hematology and Oncology, Helios Hospital Berlin Buch, 13125 Berlin, Germany.
Brossart P; Department of Internal Medicine, Oncology, Hematology, Immuno-Oncology and Rheumatology/Clinical Immunology, University Hospital Bonn, 53127 Bonn, Germany.
Goerner M; Department of Hematology, Oncology and Palliative Care, Klinikum Bielefeld, 33604 Bielefeld, Germany.
Bernhard H; Internal Medicine V, Klinikum Darmstadt, 64283 Darmstadt, Germany.
Raab MS; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.
Blau IW; Medical Clinic, Charité University Medicine Berlin, 13353 Berlin, Germany.
Haenel M; Department of Internal Medicine III, Klinikum Chemnitz, 09116 Chemnitz, Germany.
Scheid C; Department of Internal Medicine I, University Hospital Cologne, 50937 Cologne, Germany.
Goldschmidt H; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.; National Center for Tumor Diseases, 69120 Heidelberg, Germany.
On Behalf Of The German-Speaking Myeloma Multicenter Group Gmmg
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2021 Sep 28; Vol. 13 (19). Date of Electronic Publication: 2021 Sep 28.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment.
Autorzy:
Ghandili S; University Cancer Center Hamburg, Department of Oncology, Hematology and Bone Marrow Transplantation, Section of Pneumology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
Schönlein M; University Cancer Center Hamburg, Department of Oncology, Hematology and Bone Marrow Transplantation, Section of Pneumology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
Lütgehetmann M; The Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
Schulze Zur Wiesch J; Department of Internal Medicine, Division of Infectious Diseases, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
Becher H; Institute for Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
Bokemeyer C; University Cancer Center Hamburg, Department of Oncology, Hematology and Bone Marrow Transplantation, Section of Pneumology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
Sinn M; University Cancer Center Hamburg, Department of Oncology, Hematology and Bone Marrow Transplantation, Section of Pneumology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
Weisel KC; University Cancer Center Hamburg, Department of Oncology, Hematology and Bone Marrow Transplantation, Section of Pneumology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
Leypoldt LB; University Cancer Center Hamburg, Department of Oncology, Hematology and Bone Marrow Transplantation, Section of Pneumology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2021 Jul 28; Vol. 13 (15). Date of Electronic Publication: 2021 Jul 28.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma.
Autorzy:
Radocha J; 4th Department of Internal Medicine-Hematology, Faculty of Medicine in Hradec Králové, University Hospital Hradec Kralove, Charles University, 50005 Hradec Kralove, Czech Republic.
van de Donk NWCJ; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands.
Weisel K; II Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf, 20251 Hamburg, Germany.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2021 Mar 29; Vol. 13 (7). Date of Electronic Publication: 2021 Mar 29.
Typ publikacji:
Journal Article; Review
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Current Treatment Approaches to Newly Diagnosed Multiple Myeloma.
Autorzy:
Ghandili S; Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Weisel KC; Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Bokemeyer C; Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Leypoldt LB; Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Pokaż więcej
Źródło:
Oncology research and treatment [Oncol Res Treat] 2021; Vol. 44 (12), pp. 690-699. Date of Electronic Publication: 2021 Nov 16.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Multiple Myeloma*/diagnosis
Multiple Myeloma*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Lenalidomide ; Transplantation, Autologous
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Outcome of a Real-World Patient Cohort with Secondary CNS Lymphoma Treated with High-Intensity Chemoimmunotherapy and Autologous Stem Cell Transplantation.
Autorzy:
Thiele B; Department of Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, .
Binder M; Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University, Halle-Wittenberg, Halle (Saale), Germany.
Schliffke S; Department of Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Frenzel C; Department of Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Dierlamm J; Department of Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Wass M; Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University, Halle-Wittenberg, Halle (Saale), Germany.
Weisel KC; Department of Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Bokemeyer C; Department of Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Janjetovic S; Department of Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Pokaż więcej
Źródło:
Oncology research and treatment [Oncol Res Treat] 2021; Vol. 44 (7-8), pp. 375-381. Date of Electronic Publication: 2021 Jul 21.
Typ publikacji:
Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Lymphoma*/therapy
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Germany ; Humans ; Immunotherapy ; Neoplasm Recurrence, Local/drug therapy ; Retrospective Studies ; Transplantation, Autologous ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma.
Autorzy:
Yan X; Faculty of Medicine, School of Pharmacy, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, Hong Kong.
Xu XS; Janssen Research and Development, Raritan, Princeton, New Jersey, USA.
Weisel KC; Universitätsklinikum Hamburg - Eppendorf II. Medizinische Klinik und Poliklinik, Hamburg, Germany.; University of Tuebingen, Tuebingen, Germany.
Mateos MV; University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.
Sonneveld P; Department of Hematology, Erasmus Medical Center, Rotterdam, Netherlands.
Dimopoulos MA; National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
Usmani SZ; Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina, USA.
Bahlis NJ; Arnie Charbonneau Cancer Institute, University of Calgary Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Puchalski T; Janssen Research and Development, Spring House, Pennsylvania, USA.
Ukropec J; Janssen Research and Development, Spring House, Pennsylvania, USA.
Bellew K; Janssen Research and Development, Spring House, Pennsylvania, USA.
Ming Q; Janssen Research and Development, Spring House, Pennsylvania, USA.
Sun S; Janssen Research and Development, Raritan, Princeton, New Jersey, USA.
Zhou H; Janssen Research and Development, Spring House, Pennsylvania, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2020 Nov; Vol. 13 (6), pp. 1345-1354. Date of Electronic Publication: 2020 Jul 17.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal/*pharmacology
Biomarkers, Tumor/*blood
Multiple Myeloma/*mortality
Myeloma Proteins/*analysis
Neoplasm Recurrence, Local/*mortality
Adult ; Antibodies, Monoclonal/therapeutic use ; Clinical Trials, Phase III as Topic ; Drug Resistance, Neoplasm ; Female ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Multicenter Studies as Topic ; Multiple Myeloma/blood ; Multiple Myeloma/drug therapy ; Neoplasm Recurrence, Local/blood ; Neoplasm Recurrence, Local/drug therapy ; Progression-Free Survival ; Prospective Studies ; Randomized Controlled Trials as Topic ; Reference Values ; Risk Assessment/methods
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects.
Autorzy:
Jansen L; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Merz M; Medizinische Klinik V, University Hospital Heidelberg, Heidelberg, Germany.
Engelhardt M; Universitätsklinikum Freiburg, Freiburg, Germany.
Weisel K; II. Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
Scheid C; Universitätsklinikum Köln, Köln, Germany.
Straka C; München Klinik Schwabingen, München, Germany.
Langer C; Klinikum Kempten, Kempten, Germany.
Salwender H; Asklepios Kliniken Altona und St. Georg, Hamburg, Germany.
Einsele H; Universitätsklinikum Würzburg, Würzburg, Germany.
Kröger N; Interdisziplinäre Klinik für Stammzelltransplantation, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
Beelen DW; Klinik für Knochenmarktransplantation des Universitätsklinikums Essen, Essen, Germany.
Dreger P; Medizinische Klinik V, University Hospital Heidelberg, Heidelberg, Germany.
Goldschmidt H; Medizinische Klinik V, University Hospital Heidelberg, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Brenner H; Medizinische Klinik V, University Hospital Heidelberg, Heidelberg, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Pokaż więcej
Corporate Authors:
German National Registry for Stem Cell Transplants (DRST)
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2020 Oct; Vol. 61 (10), pp. 2365-2374. Date of Electronic Publication: 2020 May 30.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Multiple Myeloma*/epidemiology
Multiple Myeloma*/therapy
Germany/epidemiology ; Hospitals ; Humans ; Middle Aged ; Retrospective Studies ; Stem Cell Transplantation ; Transplantation, Autologous ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk.
Autorzy:
Weisel K; Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. k.weisel@uke.de.
Spencer A; Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia.
Lentzsch S; Division of Hematology/Oncology, Columbia University, New York, NY, USA.
Avet-Loiseau H; Unite de Genomique du Myelome, CHU Rangueil, Toulouse, France.
Mark TM; Department of Medicine, University of Colorado, Aurora, CO, USA.
Spicka I; Clinical Department of Haematology, 1st Medical Department, Charles University in Prague, Prague, Czech Republic.
Masszi T; László Hospital, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
Lauri B; Department of Hematology, Sunderbyn Hospital, Luleå, Sweden.
Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
Bosi A; Department of Hematology, Careggi Hospital and University of Florence, Firenze, Italy.
Hungria V; Irmandade Da Santa Casa De Misericordia De São Paulo, São Paulo, Brazil.
Cavo M; 'Seràgnoli' Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Lee JJ; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo, South Korea.
Nooka A; Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Quach H; University of Melbourne, St Vincent's Hospital, Melbourne, Australia.
Munder M; University Medical Center of the Johannes Gutenberg University, Third Department of Medicine, Mainz, Germany.
Lee C; Royal Adelaide Hospital, North Terrace, Adelaide, Australia.
Barreto W; University of São Paulo, Ribeirão Preto, Brazil.
Corradini P; Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan, Italy.
Min CK; Seoul St. Mary's Hospital, Seoul, South Korea.
Chanan-Khan AA; Mayo Clinic Florida, Jacksonville, FL, USA.
Horvath N; Royal Adelaide Hospital, North Terrace, Adelaide, Australia.
Capra M; Instituto do Cancer-Hospital Mae de Deus, Porto Alegre, Brazil.
Beksac M; Ankara University, Ankara, Turkey.
Ovilla R; Hospital Angeles Lomas, Naucalpan de Juárez y alrededores, Mexico.
Jo JC; Ulsan University Hospital, Ulsan, South Korea.
Shin HJ; Department of Internal Medicine, Pusan National University Hospital, Busan, South Korea.
Sonneveld P; Erasmus MC, Rotterdam, The Netherlands.
Casneuf T; Janssen Research & Development, LLC, Beerse, Belgium.
DeAngelis N; Janssen Research & Development, LLC, Spring House, PA, USA.
Amin H; Janssen Research & Development, LLC, Raritan, NJ, USA.
Ukropec J; Janssen Global Scientific Affairs, Horsham, PA, USA.
Kobos R; Janssen Research & Development, LLC, Raritan, NJ, USA.
Mateos MV; University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain.
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2020 Aug 20; Vol. 13 (1), pp. 115. Date of Electronic Publication: 2020 Aug 20.
Typ publikacji:
Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Multiple Myeloma/*drug therapy
Abnormal Karyotype ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/administration & dosage ; Bortezomib/administration & dosage ; Dexamethasone/administration & dosage ; Female ; Follow-Up Studies ; Humans ; In Situ Hybridization, Fluorescence ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Multiple Myeloma/genetics ; Multiple Myeloma/pathology ; Neoplasm, Residual ; Progression-Free Survival ; Recurrence ; Risk
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Autorzy:
Weisel K; University Medical Center of Hamburg-Eppendorf, Hamburg, Germany and University Hospital of Tuebingen, Tuebingen, Germany.
Dimopoulos M; National and Kapodistrian University of Athens, Athens, Greece.
Moreau P; University Hospital Hôtel-Dieu, Nantes, France.
Yagci M; Gazi Universitesi Tip Fakultesi Hastanesi, Besevler, Turkey.
Larocca A; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
Kanate AS; Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, USA.
Vural F; Ege University Hospital, Izmir, Turkey.
Cascavilla N; Fondazione IRCSS Casa Sollievo Della Sofferenza, San Giovanni Rotundo, Italy.
Basu S; New Cross Hospital, Wolverhampton, University Of Wolverhampton, United Kingdom.
Johnson P; Department of Haematology, Western General Hospital, Edinburgh, United Kingdom.
Byeff P; Cancer Center of Central Connecticut, Southington, CT, USA.
Hus M; Samodzielny Publiczny Szpital Nr 1 W Lublinie, Lublin, Poland.
Rodríguez-Otero P; University of Navarra, Pamplona, Spain.
Muelduer E; Medizinische Universitaet Wien, Vienna, Austria.
Anttila P; Division of Hematology, Helsinki University and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Hayden PJ; St James Hospital-Cancer Clinical Trials Office, Dublin, Ireland.
Krauth MT; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Lucio P; Champalimaud Center for the Unknown, Lisbon, Portugal.
Ben-Yehuda D; Hadassah Hospital, Jerusalem, Israel.
Mendeleeva L; National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russia.
Guo S; Evidera, Waltham, MA, USA.
Yu X; Bristol Myers Squibb, Summit, NJ, USA.
Grote L; Bristol Myers Squibb, Summit, NJ, USA.
Biyukov T; Celgene International Sàrl, a Bristol Myers Squibb Company, Boudry, Switzerland.
Dhanasiri S; Celgene International Sàrl, a Bristol Myers Squibb Company, Boudry, Switzerland.
Richardson P; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2020 Aug; Vol. 61 (8), pp. 1850-1859. Date of Electronic Publication: 2020 Apr 09.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Multiple Myeloma*/drug therapy
Quality of Life*
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib/therapeutic use ; Dexamethasone/therapeutic use ; Humans ; Neoplasm Recurrence, Local/drug therapy ; Thalidomide/analogs & derivatives
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 48

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies